ArticleJournal of comparative effectiveness research2023

Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome.

Teri J Mauch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.